{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:23:34Z","timestamp":1780752214968,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":853,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/jto.0b013e318294c8e8","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T11:18:29Z","timestamp":1372245509000},"page":"1069-1074","source":"Crossref","is-referenced-by-count":95,"title":["Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Eunyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318294c8e8_bib1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","article-title":"EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer","volume":"12","author":"Eichler","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0030-1255220","article-title":"Leptomeningeal metastasis","volume":"30","author":"Chamberlain","year":"2010","journal-title":"Semin Neurol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11864-012-0206-4","article-title":"Treatment of leptomeningeal spread of NSCLC: a continuing challenge","volume":"13","author":"Nagpal","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI","volume":"65","author":"Yi","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib9","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","article-title":"Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib","volume":"24","author":"Jackman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib12","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib","volume":"23","author":"Han","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.suponc.2011.06.002","article-title":"Neoplastic meningitis","volume":"10","author":"Van Horn","year":"2012","journal-title":"J Support Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib14","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","article-title":"High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib","volume":"103","author":"Omuro","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/00498250500523253","article-title":"Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition","volume":"36","author":"McKillop","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","article-title":"Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib","volume":"4","author":"Katayama","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib19","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1200\/JCO.2008.21.0963","article-title":"Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib","volume":"27","author":"Dhruva","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-007-0494-8","article-title":"Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318294c8e8_bib21","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641533447X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641533447X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T01:29:01Z","timestamp":1539566941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641533447X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S155608641533447X"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318294c8e8","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}